Emergent BioSolutions Inc. EBS
NYSE · XNYS · stock · Pharmaceutical Preparations
Chart by TradingView
7/9
Piotroski F — financial health
3.44
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $742.9M | $52.6M | — | $156.8M | $522.6M |
| 2024 | $1.0B | -$190.6M | — | $35.8M | $482.8M |
| 2023 | $1.0B | -$760.5M | $317.6M | -$257.9M | $649.3M |
| 2022 | $1.1B | -$211.6M | $383.0M | -$149.9M | $1.4B |
| 2021 | $1.8B | $219.5M | $891.3M | $96.1M | $1.6B |
| 2020 | $1.6B | $305.1M | $916.3M | $395.0M | $1.5B |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.44 (safe)
- Working capital / assets 0.402
- Retained earnings / assets -0.121
- EBIT / assets 0.076
- Equity / liabilities 0.657
Source: SEC EDGAR filings · CIK 0001367644 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.